NCT03407170终止2 期
An Open-Label, Phase II Study to Determine the Immunologic Correlates of Pembrolizumab-Mediated Tumor Regression in Subjects With Advanced Melanoma (KEYNOTE-161)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 4
- 主要终点
- Average Specific Cytotoxic T-lymphocyte Frequency Ratio (ASCTFR) for Participants With Response Versus Participants With Progression
研究概览
简要总结
In this study, participants with advanced melanoma will be treated with pembrolizumab (MK-3475) and their tumors and blood will be analyzed for changes related to pembrolizumab therapy.
The primary hypotheses are that participants who respond to pembrolizumab have:
- a higher fraction of cytotoxic tumor-infiltrating T-lymphocytes (FCT) at baseline compared to those who do not respond to pembrolizumab
- a higher fold-increase in FCT compared to baseline than those who do not respond to pembrolizumab
- a higher Average Specific Cytotoxic T-lymphocyte Frequency Ratio (ASCTFR) compared to those who do not respond to pembrolizumab
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has a histologically confirmed diagnosis of unresectable stage III or metastatic melanoma not amenable to local therapy
- •Has testing for a BRAF mutation prior to study entry
- •Has measurable disease per RECIST 1.1 as assessed by the investigator/radiology
- •Has resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If the participant received major surgery or radiation therapy of >30 Gray units, they must have recovered from the toxicity and/or complications from the intervention
- •Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 10 days of study start
- •A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of childbearing potential (WOCBP) OR is a WOCBP and agrees to use a contraceptive method, consistent with local regulations regarding the methods of contraception for those participating in clinical studies, during the treatment period and for at least 120 days after the last dose of study treatment
- •A male participant is eligible to participate if he agrees not to donate sperm PLUS to be abstinent from heterosexual intercourse as their preferred and usual lifestyle OR agree to use contraception, consistent with local regulations regarding the methods of contraception for those participating in clinical studies, during the treatment period and for at least 120 days after the last dose of study treatment
排除标准
- •Has disease that is suitable for local therapy administered with curative intent
- •Has a history of interstitial lung disease
- •Has a positive pregnancy test within 72 hours before the first dose of study therapy
- •Has received prior therapy with an anti-Programmed Cell Death Protein 1 (PD-1), anti-Programmed Cell Death-Ligand 1 (PD-L1), anti-Programmed Cell Death-Ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137)
- •Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to study start
- •Has received prior radiotherapy within 2 weeks of start of study therapy
- •Has received a live vaccine within 30 days prior to the first dose of study therapy
- •Has received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including granulocyte colony stimulating factor [G-CSF], granulocyte macrophage colony stimulating factor [GMCSF] or recombinant erythropoietin) within 4 weeks prior to study start
- •Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study therapy
- •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study therapy
- •Has a known additional malignancy that is progressing or has required active treatment within the past 3 years with the exception of basal cell and squamous cell carcinoma of the skin, transitional cell carcinoma of urothelial cancer, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy
- •Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- •Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients
- •Has an active autoimmune disease that has required systemic treatment in past 2 years
- •Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
- •Has an active infection requiring systemic therapy
- •Has a known history of human immunodeficiency virus (HIV) infection
- •Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
- •Has known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the study
- •Is pregnant or breastfeeding or expecting to conceive or father children starting with the screening visit through 120 days after the last dose of study therapy
结局指标
主要结局
Average Specific Cytotoxic T-lymphocyte Frequency Ratio (ASCTFR) for Participants With Response Versus Participants With Progression
时间窗: Up to approximately 59 weeks
ASCTFR is defined as the arithmetic average of the log10 ratio of the frequency of individual specific cytotoxic T-Cell Receptor (TCR) clones of on-treatment to pre-treatment.
Change in Baseline of Fraction of Cytotoxic T-lymphocytes (FCT) for Participants With Response Versus Participants With Progression
时间窗: Up to approximately 59 weeks
The fold change from baseline in FCT. FCT is defined as the fraction of CD8+ T-cells expressing a predefined single-cell RNA gene signature to the total tumor infiltrating CD8+T-cells isolated from tumor biopsies.
Mean Fraction of Cytotoxic T-lymphocytes (FCT) for Participants With Response Versus Participants With Progression
时间窗: Up to approximately 59 weeks
FCT is defined as the fraction of CD8+ T-cells expressing a predefined single-cell ribonucleic acid (RNA) gene signature to the total tumor infiltrating CD8+T-cells isolated from tumor biopsies.
次要结局
- Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1(Up to approximately 59 weeks)
- Number of Participants Who Experienced an Adverse Event (AE)(Up to approximately 59 weeks)
- Overall Survival (OS)(Up to approximately 59 weeks)
- Antigenic Determinants of Highly-functional CD8 + T-cell Clones(Up to approximately 59 weeks)
- Number of Participants Who Discontinued Any Study Drug Due to an Adverse Event (AE)(Up to approximately 59 weeks)
- Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1(Up to approximately 59 weeks)
- Neoepitope Burden(Up to approximately 59 weeks)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
Pembrolizumab +/- Bevacizumab for Recurrent GBMGlioblastomaNCT02337491Dana-Farber Cancer Institute80
Unknown
2 期
Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.Non Small Cell Lung Cancer (NSCLC)NCT03447678Fondazione IRCCS Istituto Nazionale dei Tumori, Milano65
终止
2 期
Pembrolizumab in Treating Patients With Advanced Uveal MelanomaStage IIIA Uveal MelanomaStage IIIB Uveal MelanomaStage IIIC Uveal MelanomaStage IV Uveal MelanomaNCT02359851Vanderbilt-Ingram Cancer Center5
已完成
2 期
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV MelanomaUnresectable Malignant NeoplasmMetastatic MelanomaStage IV MelanomaStage III MelanomaMelanomaNCT02306850St. Louis University10
已完成
2 期
Pembrolizumab in Patients With Locally Advanced or Metastatic Skin CancerRecurrent Skin CarcinomaSkin Squamous Cell CarcinomaNCT02964559Emory University11